Inhibitors of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease for COVID-19 | Hai Feng

Summary :
⁣Since the outbreak of the 2019 novel coronavirus disease (COVID-19), the medical research community is vigorously seeking a treatment to control the infection and save the lives of severely infected patients. The main potential candidates for the control of viruses are virally targeted agents. In this short letter, we report our calculations on the inhibitors for the SARS-CoV-2 3CL protease and the spike protein for the potential treatment of COVID-19. The results show that the most potent inhibitors of the SARS-CoV-2 3CL protease include saquinavir, tadalafil, rivaroxaban, sildenafil, dasatinib, etc. Ergotamine, amphotericin b, and vancomycin are most promising to block the interaction of the SARS-CoV-2 S-protein with human ACE-2.


About Author :
⁣Dr. Hai-Feng (Frank) Ji is current a professor of Department of Chemistry, Drexel university. His research interests focus on drug discovery, MEMS devices, nanomaterials for energy and environmental applications, nanopillars and phosphene for energy applications, and surface chemistry. He is currently a co-author of 190 peer-viewed journal articles and book chapters. He has an H-index of 37. He is an editorial board member of several chemistry journals.